It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG for pheochromocytoma and paraganglioma.
‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results From a Pivotal Phase 2 Clinical Trial’ (PRESENTATION NUMBER: OR04-3) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
Questions
- What role are tumour biomarkers likely to play in the future use of I-131MIBG in this patient population? (0:22)
- What will be the next step in the clinical development of I-131 MIBG? (2:40)
Disclosures: Professor Camilo Jimenez is a principal investigator of phase 2 and phase 4 clinical trials with high specific activity MIBG for patients with metastatic pheochromocytomas and paragangliomas and has received research support from Lantheus Pharmaceuticals.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ENDO 2021 (Virtual).
